A Meta-Analysis of Migraine Treated with Banxia Baizhu Tianma Decoction

Abstract

Objective Our objective was to systematically evaluate the efficacy and safety of Banxia Baizhu Tianma decoction in the treatment of migraine. Methods The databases of China National Knowledge Infrastructure, VIP, WanFang, Chinese Biomedical Databases, PubMed, and EMbase were searched by computer, and randomized controlled trials that met the inclusion criteria were retrieved. The Cochrane bias risk assessment tool was used to evaluate the quality of the included studies. RevMan 5.3 software was used to conduct meta quantitative analysis of the included studies. Results A total of 19 studies were included, with a total sample size of 1,635 cases, 821 cases in the treatment group and 814 cases in the control group. The results of meta-analysis showed that (1) the clinical effective rate of the single use of Banxia Baizhu Tianma decoction or western medicine combined with Banxia Baizhu Tianma decoction in treating migraine was better than that of western medicine alone (p < 0.001); (2) the improvement in cumulative number and days of vertigo in the treatment of migraine with Banxia Baizhu Tianma decoction was observed in the control group (p < 0.001). TSA results showed that Z-curve passed both the traditional threshold and Trial sequential analysis (TSA) threshold. In terms of adverse reactions, 55 cases were reported, including 12 cases in the treatment group and 43 cases in the control group, and no serious adverse reactions were found. Conclusion Compared with the single use of western medicine therapy, the combination of Banxia Baizhu Tianma decoction and western medicine or the single use of Banxia Baizhu Tianma decoction could better improve the effective rate and showed good safety and low incidence of adverse reactions.